In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011

Executive Summary

During the second quarter of 2011, 57 medical device companies brought in a total of $1.7 billion in financings. The M&A activity reached $28.8 billion, unusually high due to Johnson & Johnson's $21.7 billion takeover of orthopedic device maker Synthes. VC funding represented $76 million or 43% of the second quarter's in vitro diagnostics/research financing aggregate of $177 million. A hefty $4.1 billion was spent on 11 in vitro diagnostic/research M&A transactions, the largest being Thermo Fisher's $3.5 billion buy of Swedish genetics testing firm Phadia AB.
Advertisement

Related Content

Is Diagnostics the New Biotech...and Will Pharma Embrace It?
SeptRx Inc.
Dentsply Doubles Dental Implant Biz With $1.8 Billion Astra Tech Acquisition
Stryker Buys Memometal For Broader Access To $1 Bil. Extremities Market
Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz
Thermo Fisher Underscores Allergy Test Opportunity With $3.5 Bil. Phadia Deal
J&J Doubles Down On Orthopedics With Synthes Deal; Takes Lead In Trauma
J&J Renews Commitment To Devices With Synthes Deal
Cameron Health: Is This The Cure For An Ailing ICD Market?
The How And When Of Applying Sequencing To Clinical Diagnostics

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel